Dr. Selig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Boston, MA 02115Phone+1 617-525-6841
Education & Training
University of Colorado School of Medicine Anschutz Medical CampusClass of 2007
Brigham and Women's HospitalResidency, Internal Medicine
Certifications & Licensure
MA State Medical License 2007 - 2012
Publications & Presentations
PubMed
- 4 citationsThe aberrant epigenome of-mutated ICF1 patient iPSCs is amenable to correction, with the exception of a subset of regions with H3K4me3- and/or CTCF-based epigenetic me...Varsha Poondi Krishnan, Barbara Morone, Shir Toubiana, Monika Krzak, Salvatore Fioriniello
Genome Research. 2023-02-01 - 2 citationsRBL2 bi-allelic truncating variants cause severe motor and cognitive impairment without evidence for abnormalities in DNA methylation or telomeric function.Nadra Samra, Shir Toubiana, Hilde Yttervik, Aya Tzur-Gilat, Ilham Morani
Journal of Human Genetics. 2021-05-13 - 2 citationsEpigenetic Characteristics of Human Subtelomeres Vary in Cells Utilizing the Alternative Lengthening of Telomeres (ALT) Pathway.Shir Toubiana, Aya Tzur-Gilat, Sara Selig
Life. 2021-03-26
Press Mentions
Immunocore Announces FDA Approval of KIMMTRAK® (Tebentafusp-Tebn) for the Treatment of Unresectable or Metastatic Uveal MelanomaJanuary 27th, 2022- Melanoma Research Foundation Launches Historic Patient-Reported Ocular Melanoma RegistryMay 10th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
